Results 191 to 200 of about 65,280 (255)

Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments

European Journal of Haematology, EarlyView.
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by a defect of glycosylphosphatidyl‐anchored proteins, leading to an uncontrolled complement‐mediated hemolysis. The advent of complement inhibitors in clinical practice radically changed patients' outcomes and survival.
Bruno Fattizzo, Monia Marchetti, Elisa Cannizzo, Arianna Gatti, Massimo Geuna, Anna Paola Iori, Maddalena Raia, Simona Sica, Francesco Buccisano   +8 more
wiley   +1 more source

Spectrum of constitutional chromosomal disorders: A five-year retrospective analysis from a tertiary care center in Karachi. [PDF]

Pak J Med Sci
Aman S, Mujtaba M, Naz M, Mansoor N.
europepmc   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. [PDF]

Bone Marrow Transplant
Oswald LB, Li X, Gudenkauf LM, De Avila G, Scheiber-Camoretti D, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker NH, Carson TL, Vinci CE, Baz RC, Shain KH, Blue B, Grajales-Cruz A, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini O, Nishihori T, Liu H, Locke FL, Jim HSL, Peres LC, Hansen DK.   +30 more
europepmc   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann, Sarah Flossdorf, Julius Keyl, Theo Leitner, Cyrus Khandanpour, Markus Maulhardt, Evgenii Shumilov, Matthias Stelljes, Lisa Leypoldt, Marie Harzer, Christoph Schaefers, Francis Ayuketang Ayuk, Bastian von Tresckow, Amelie Boquoi, Thomas Schroeder, Hans Christian Reinhardt, Christine Hanoun   +16 more
wiley   +1 more source

Finding the genes that fit CPX-351. [PDF]

Blood Adv
Hanamshet A, Othman J.
europepmc   +1 more source

Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE Study

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The MYLENE non‐interventional study (NIS) aimed to close the gap in real‐world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non‐transplant eligible multiple myeloma in Germany.
Eyck von der Heyde, Marcel Reiser, Vanessa Baumgartner, Christian Englisch, Oliver Frank, Sabrina Buchholz, Fabian Kreimendahl, Jens Uhlig, Dieter Bürkle, Wolfgang Knauf   +9 more
wiley   +1 more source

Prognostic Significance of Peripheral Blood Neutrophil-To-Lymphocyte Ratio (NLR), Monocyte-To-Lymphocyte Ratio (MLR), and Platelet-To-Lymphocyte Ratio (PLR) in Patients With Multiple Myeloma: A Retrospective Cohort Study. [PDF]

J Clin Lab Anal
Zhang L, Ma B, Zhang J.
europepmc   +1 more source

BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

European Journal of Haematology, EarlyView.
ABSTRACT Objectives B‐cell maturation antigen (BCMA)‐targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real‐world impact within EMMY, a French longitudinal cohort. Methods Patients initiating a fourth or later line of therapy (L4+) between
Titouan Cazaubiel, Olivier Decaux, Aurore Perrot, Bruno Royer, Karim Belhadj‐Merzoug, Margaret Macro, Laure Vincent, Lionel Karlin, Arthur Bobin, Thomas Chalopin, Mohamad Mohty, Laurent Frenzel, Julie Gay, Cécile Sonntag, Jean Fontan, Olivier Allangba, Cyrille Touzeau, Hélène Demarquette, Jean‐Valère Malfuson, Claire Jouzier, Stéphane Darre, Benoit Bareau, Ariane Boumendil, Cyrille Hulin, on behalf of EMMY and the IFM group   +24 more
wiley   +1 more source

First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups. [PDF]

Front Immunol
Zhong D, Cheng H, Zeng L, Tian C, Liang C, Wei H, Xu M, Pang M, Ke Q, Tan X, Cen H, Liao C.   +11 more
europepmc   +1 more source